ES2773017T3 - Derivados de quitosano para el tratamiento de mucositis o ulceración - Google Patents
Derivados de quitosano para el tratamiento de mucositis o ulceración Download PDFInfo
- Publication number
- ES2773017T3 ES2773017T3 ES11766639T ES11766639T ES2773017T3 ES 2773017 T3 ES2773017 T3 ES 2773017T3 ES 11766639 T ES11766639 T ES 11766639T ES 11766639 T ES11766639 T ES 11766639T ES 2773017 T3 ES2773017 T3 ES 2773017T3
- Authority
- ES
- Spain
- Prior art keywords
- chitosan
- soluble
- alkyl substituted
- group
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C=*C([C@](Cc1c[n]cn1)N)=O Chemical compound C=*C([C@](Cc1c[n]cn1)N)=O 0.000 description 14
- UWJHYSALJZAQEU-SCSAIBSYSA-N CC([C@@H](CNC(N)=N)N)=O Chemical compound CC([C@@H](CNC(N)=N)N)=O UWJHYSALJZAQEU-SCSAIBSYSA-N 0.000 description 3
- FADKJNSSIWTVAI-ZETCQYMHSA-N CC([C@H](CCCCN)N)=O Chemical compound CC([C@H](CCCCN)N)=O FADKJNSSIWTVAI-ZETCQYMHSA-N 0.000 description 3
- UWJHYSALJZAQEU-BYPYZUCNSA-N CC([C@H](CNC(N)=N)N)=O Chemical compound CC([C@H](CNC(N)=N)N)=O UWJHYSALJZAQEU-BYPYZUCNSA-N 0.000 description 3
- QRGDXQZAJYUBFH-ZCFIWIBFSA-N C=NC([C@@H](Cc1c[nH]cn1)N)=O Chemical compound C=NC([C@@H](Cc1c[nH]cn1)N)=O QRGDXQZAJYUBFH-ZCFIWIBFSA-N 0.000 description 2
- FADKJNSSIWTVAI-SSDOTTSWSA-N CC([C@@H](CCCCN)N)=O Chemical compound CC([C@@H](CCCCN)N)=O FADKJNSSIWTVAI-SSDOTTSWSA-N 0.000 description 2
- HZWRYORYOPIUPM-YFKPBYRVSA-N CC([C@H](CCNC(N)=N)N)=O Chemical compound CC([C@H](CCNC(N)=N)N)=O HZWRYORYOPIUPM-YFKPBYRVSA-N 0.000 description 2
- QQBWOUNMLHBTEP-UHFFFAOYSA-N CC(C)C(C(CCN)N)=O Chemical compound CC(C)C(C(CCN)N)=O QQBWOUNMLHBTEP-UHFFFAOYSA-N 0.000 description 1
- UNYDWXGETNKFSJ-UHFFFAOYSA-N CC(C)C(CN)=O Chemical compound CC(C)C(CN)=O UNYDWXGETNKFSJ-UHFFFAOYSA-N 0.000 description 1
- HRGWZWKIYNBDFH-SSDOTTSWSA-N CC(C)C([C@@H](CCCN)N)=O Chemical compound CC(C)C([C@@H](CCCN)N)=O HRGWZWKIYNBDFH-SSDOTTSWSA-N 0.000 description 1
- QQBWOUNMLHBTEP-ZCFIWIBFSA-N CC(C)C([C@@H](CCN)N)=O Chemical compound CC(C)C([C@@H](CCN)N)=O QQBWOUNMLHBTEP-ZCFIWIBFSA-N 0.000 description 1
- QQBWOUNMLHBTEP-LURJTMIESA-N CC(C)C([C@H](CCN)N)=O Chemical compound CC(C)C([C@H](CCN)N)=O QQBWOUNMLHBTEP-LURJTMIESA-N 0.000 description 1
- UNJPSUGDAVDBGM-YFKPBYRVSA-N CC(C)C([C@H](CN)N)=O Chemical compound CC(C)C([C@H](CN)N)=O UNJPSUGDAVDBGM-YFKPBYRVSA-N 0.000 description 1
- QSQZITWBCATKMY-UHFFFAOYSA-N CC(CCCCCNC(N)=N)=O Chemical compound CC(CCCCCNC(N)=N)=O QSQZITWBCATKMY-UHFFFAOYSA-N 0.000 description 1
- FOEIDSRVZBWXAC-UHFFFAOYSA-N CC(CCCCNC(N)=N)=O Chemical compound CC(CCCCNC(N)=N)=O FOEIDSRVZBWXAC-UHFFFAOYSA-N 0.000 description 1
- KWIFGEMEMQTMAV-UHFFFAOYSA-N CC(CCCNC(N)=N)=O Chemical compound CC(CCCNC(N)=N)=O KWIFGEMEMQTMAV-UHFFFAOYSA-N 0.000 description 1
- VUNFQOJHWNMKFQ-UHFFFAOYSA-N CC(CCNC(N)=N)=O Chemical compound CC(CCNC(N)=N)=O VUNFQOJHWNMKFQ-UHFFFAOYSA-N 0.000 description 1
- QNRGQNWTRMBZLO-UHFFFAOYSA-N CC(CNC=N)=O Chemical compound CC(CNC=N)=O QNRGQNWTRMBZLO-UHFFFAOYSA-N 0.000 description 1
- GCCQNSQKSSOQIR-ZCFIWIBFSA-N CC([C@@H](CCCNC(N)=N)N)=O Chemical compound CC([C@@H](CCCNC(N)=N)N)=O GCCQNSQKSSOQIR-ZCFIWIBFSA-N 0.000 description 1
- HZWRYORYOPIUPM-RXMQYKEDSA-N CC([C@@H](CCNC(N)=N)N)=O Chemical compound CC([C@@H](CCNC(N)=N)N)=O HZWRYORYOPIUPM-RXMQYKEDSA-N 0.000 description 1
- BLKFEXKSMJLHDD-SSDOTTSWSA-N CC([C@@H](Cc1c[nH]cn1)N)=O Chemical compound CC([C@@H](Cc1c[nH]cn1)N)=O BLKFEXKSMJLHDD-SSDOTTSWSA-N 0.000 description 1
- YWUYIHDJQRWFLW-LURJTMIESA-N CC([C@H](CCCNC(N)N)N)=O Chemical compound CC([C@H](CCCNC(N)N)N)=O YWUYIHDJQRWFLW-LURJTMIESA-N 0.000 description 1
- BLKFEXKSMJLHDD-ZETCQYMHSA-N CC([C@H](Cc1c[nH]cn1)N)=O Chemical compound CC([C@H](Cc1c[nH]cn1)N)=O BLKFEXKSMJLHDD-ZETCQYMHSA-N 0.000 description 1
- UWBJBRABTNYSRB-UHFFFAOYSA-O CCC(C(CNC)[NH3+])O Chemical compound CCC(C(CNC)[NH3+])O UWBJBRABTNYSRB-UHFFFAOYSA-O 0.000 description 1
- XCGWKTYFWPRZLU-RXMQYKEDSA-N CCC([C@@H](CCNC(N)=N)N)=O Chemical compound CCC([C@@H](CCNC(N)=N)N)=O XCGWKTYFWPRZLU-RXMQYKEDSA-N 0.000 description 1
- SCIHGFPLSAIEJP-LURJTMIESA-N CCC([C@H](CCCN)N)=O Chemical compound CCC([C@H](CCCN)N)=O SCIHGFPLSAIEJP-LURJTMIESA-N 0.000 description 1
- NNXNMPWMDXZADP-BYPYZUCNSA-N CNC([C@H](CCNC(N)=N)N)=O Chemical compound CNC([C@H](CCNC(N)=N)N)=O NNXNMPWMDXZADP-BYPYZUCNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Polymers & Plastics (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32143710P | 2010-04-06 | 2010-04-06 | |
| US201161451430P | 2011-03-10 | 2011-03-10 | |
| PCT/US2011/031385 WO2011127144A1 (en) | 2010-04-06 | 2011-04-06 | Methods and compositions for treating wounds utilizing chitosan compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2773017T3 true ES2773017T3 (es) | 2020-07-09 |
Family
ID=44763261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11766639T Active ES2773017T3 (es) | 2010-04-06 | 2011-04-06 | Derivados de quitosano para el tratamiento de mucositis o ulceración |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9439925B2 (enExample) |
| EP (1) | EP2555760B1 (enExample) |
| JP (4) | JP2013523827A (enExample) |
| AU (1) | AU2011237682B2 (enExample) |
| CA (1) | CA2795520C (enExample) |
| ES (1) | ES2773017T3 (enExample) |
| WO (1) | WO2011127144A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119780B2 (en) | 2006-06-02 | 2012-02-21 | Synedgen, Inc. | Chitosan-derivative compounds and methods of controlling microbial populations |
| EP3311823B1 (en) | 2009-09-02 | 2020-11-25 | Synedgen, Inc. | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| EP2555760B1 (en) | 2010-04-06 | 2019-10-16 | Synedgen, Inc. | Chitosan derivatives for the treatment of mucositis or ulceration |
| WO2013134129A2 (en) * | 2012-03-05 | 2013-09-12 | Synedgen, Inc. | Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins |
| CN102755662B (zh) * | 2012-07-25 | 2014-01-08 | 福州乾正药业有限公司 | 一种复合壳聚糖凝胶膜及其制备方法 |
| CA2883704C (en) * | 2012-09-20 | 2021-09-28 | Synedgen, Inc. | Methods for treatment or prevention of damage resulting from radiation, trauma or shock |
| TWI478943B (zh) * | 2012-12-27 | 2015-04-01 | Ind Tech Res Inst | 高分子組成物用於製備具有抑制基質金屬蛋白酶之活性的功效的醫療器材或抑制劑的用途 |
| CN103893813B (zh) * | 2012-12-28 | 2018-04-17 | 财团法人工业技术研究院 | 高分子组合物与高分子材料 |
| WO2014165226A2 (en) | 2013-03-12 | 2014-10-09 | Synedgen, Inc. | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar |
| JP2016519667A (ja) * | 2013-03-15 | 2016-07-07 | シネジェン， インコーポレイテッド | 創傷治癒のための組成物および使用方法 |
| WO2015022907A1 (ja) * | 2013-08-13 | 2015-02-19 | 生化学工業株式会社 | カチオン化キトサンを含有する医薬 |
| US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
| EP3190886B1 (en) | 2014-09-11 | 2024-04-10 | Synedgen, Inc. | Compositions for use in the treatment of acute respiratory distress syndrome |
| WO2017072236A1 (en) * | 2015-10-30 | 2017-05-04 | Croma-Pharma Gesellschaft M.B.H. | Therapeutic use of a sterile aqueous ophthalmic solution |
| CN108348457A (zh) * | 2015-10-30 | 2018-07-31 | 克罗马药品股份有限公司 | 无菌水性眼用溶液的治疗用途 |
| WO2017161113A1 (en) * | 2016-03-16 | 2017-09-21 | Synedgen, Inc. | Compositions and methods of their use |
| CN108096182A (zh) * | 2016-11-25 | 2018-06-01 | 哈尔滨盈聚生物科技有限公司 | 一种基于绿色抗菌材料的妇科抗菌凝胶及其制备方法 |
| US10918699B2 (en) * | 2017-03-22 | 2021-02-16 | Michael C. Struck | Therapeutic treatment for neurotrophic keratopathy |
| EP3618803A1 (en) | 2017-05-03 | 2020-03-11 | Croma-Pharma GmbH | Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders |
| TWI633888B (zh) * | 2017-10-03 | 2018-09-01 | 黃琮瑋 | 醣類物質用於製備改善嗅覺功能的藥物之用途 |
| CN107970269A (zh) * | 2017-12-30 | 2018-05-01 | 广州润虹医药科技股份有限公司 | 一种含有壳聚糖的口腔溃疡膜及其制备方法 |
| RU2697869C1 (ru) * | 2018-04-28 | 2019-08-21 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Фармацевтическая субстанция для лечения инфицированных ран различного генеза |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| EP4406542A1 (en) | 2023-01-26 | 2024-07-31 | BioKuris | Treatment of gut inflammatory diseases |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4532134A (en) | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
| CA2181048C (en) * | 1994-01-14 | 2003-05-06 | Lee Shahinian, Jr. | A method for sustained and extended corneal analgesia |
| US7214202B1 (en) | 1997-07-28 | 2007-05-08 | Kci Licensing, Inc. | Therapeutic apparatus for treating ulcers |
| CA2659664C (en) | 1998-03-10 | 2013-05-07 | University Of Southern California | Improved radiation therapy methods |
| WO2000005974A1 (en) | 1998-07-30 | 2000-02-10 | E-Nutriceuticals, Inc. | Novel chitosan-containing liquid compositions and methods for their preparation and use |
| US6114382A (en) | 1998-11-11 | 2000-09-05 | Moretti; Itagiba G. | Methods for treating inflammatory bowel disease |
| ATE285751T1 (de) * | 1998-11-20 | 2005-01-15 | Medidom Lab | Wässrige ophthalmische formulierungen mit chitosan |
| US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
| JP2003012702A (ja) * | 2001-04-24 | 2003-01-15 | Sankyo Co Ltd | 低分子キトサンの製造方法 |
| CA2493083C (en) | 2002-07-16 | 2012-11-06 | Bio Syntech Canada Inc. | Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
| GB0302741D0 (en) | 2003-02-06 | 2003-03-12 | Advanced Biopolymers As | Use |
| GB0303085D0 (en) | 2003-02-11 | 2003-03-19 | Pfizer Ltd | Model |
| BRPI0513604A (pt) * | 2004-07-26 | 2008-05-13 | Kci Licensing Inc | método para revestir uma espuma para a colocação em um sìtio da ferida e método para tratar uma ferida |
| CN1965650A (zh) | 2005-11-14 | 2007-05-23 | 陈祖辉 | 多元金属离子螯合的甲壳素绿色抗菌剂 |
| US8119780B2 (en) | 2006-06-02 | 2012-02-21 | Synedgen, Inc. | Chitosan-derivative compounds and methods of controlling microbial populations |
| SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| EP2296676B1 (en) * | 2008-05-09 | 2016-11-02 | Regenics AS | Cellular extracts |
| WO2010021930A1 (en) * | 2008-08-16 | 2010-02-25 | Synedgen, Inc. | Prevention and treatment of mrsa infections with chitosan-derivatives |
| CA2732438A1 (en) | 2008-08-29 | 2010-03-04 | The General Hospital Corporation | Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| WO2010056927A1 (en) | 2008-11-12 | 2010-05-20 | Synedgen, Inc. | Chitosan derivatives alone or in combination for the treatment of mdr microbial infections |
| US8399635B2 (en) | 2008-11-12 | 2013-03-19 | Synedgen, Inc. | Chitosan derivatives to treat animals or optimize animal health |
| CA2751268A1 (en) | 2009-01-29 | 2010-08-05 | Synedgen, Inc. | Nucleic acid delivery using modified chitosans |
| RU2011152518A (ru) | 2009-06-10 | 2013-07-20 | Экстера Аб | Применение композиции для лечения мукозита |
| EP2473043B1 (en) | 2009-09-02 | 2020-03-25 | Synedgen, Inc. | Oral care methods and compositions utilizing chitosan-derivative compounds |
| EP3311823B1 (en) * | 2009-09-02 | 2020-11-25 | Synedgen, Inc. | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| EP2555760B1 (en) | 2010-04-06 | 2019-10-16 | Synedgen, Inc. | Chitosan derivatives for the treatment of mucositis or ulceration |
| US20140221308A1 (en) | 2011-07-01 | 2014-08-07 | Synedgen, Inc. | Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds |
| US8735571B2 (en) | 2011-12-22 | 2014-05-27 | Agenta Biotechnologies, Inc. | Composition, preparation, and use of dense chitosan membrane materials |
| WO2013134129A2 (en) | 2012-03-05 | 2013-09-12 | Synedgen, Inc. | Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins |
| CA2883704C (en) | 2012-09-20 | 2021-09-28 | Synedgen, Inc. | Methods for treatment or prevention of damage resulting from radiation, trauma or shock |
| WO2014165226A2 (en) | 2013-03-12 | 2014-10-09 | Synedgen, Inc. | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar |
| JP2016519667A (ja) | 2013-03-15 | 2016-07-07 | シネジェン， インコーポレイテッド | 創傷治癒のための組成物および使用方法 |
| EP3190886B1 (en) | 2014-09-11 | 2024-04-10 | Synedgen, Inc. | Compositions for use in the treatment of acute respiratory distress syndrome |
| EP3618803A1 (en) | 2017-05-03 | 2020-03-11 | Croma-Pharma GmbH | Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders |
| US11390408B2 (en) | 2020-11-24 | 2022-07-19 | Axon Llc | System and method for applying tubular bands to containers utilizing angled band ejection |
-
2011
- 2011-04-06 EP EP11766639.6A patent/EP2555760B1/en active Active
- 2011-04-06 CA CA2795520A patent/CA2795520C/en active Active
- 2011-04-06 WO PCT/US2011/031385 patent/WO2011127144A1/en not_active Ceased
- 2011-04-06 ES ES11766639T patent/ES2773017T3/es active Active
- 2011-04-06 US US13/639,560 patent/US9439925B2/en active Active
- 2011-04-06 AU AU2011237682A patent/AU2011237682B2/en active Active
- 2011-04-06 JP JP2013503881A patent/JP2013523827A/ja active Pending
-
2015
- 2015-04-06 JP JP2015077340A patent/JP6000397B2/ja active Active
- 2015-12-04 JP JP2015237188A patent/JP2016033164A/ja not_active Withdrawn
-
2016
- 2016-06-03 US US15/173,218 patent/US20170119810A1/en not_active Abandoned
-
2017
- 2017-10-05 JP JP2017194973A patent/JP2017226706A/ja not_active Withdrawn
-
2018
- 2018-03-16 US US15/923,696 patent/US11717532B2/en active Active
-
2023
- 2023-06-13 US US18/333,968 patent/US20240197769A1/en not_active Abandoned
-
2024
- 2024-12-20 US US18/989,494 patent/US20250345355A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11717532B2 (en) | 2023-08-08 |
| JP2015129189A (ja) | 2015-07-16 |
| EP2555760A4 (en) | 2013-08-21 |
| US20240197769A1 (en) | 2024-06-20 |
| EP2555760B1 (en) | 2019-10-16 |
| JP2013523827A (ja) | 2013-06-17 |
| US9439925B2 (en) | 2016-09-13 |
| JP2017226706A (ja) | 2017-12-28 |
| JP6000397B2 (ja) | 2016-09-28 |
| WO2011127144A1 (en) | 2011-10-13 |
| US20180200286A1 (en) | 2018-07-19 |
| US20250345355A1 (en) | 2025-11-13 |
| US20170119810A1 (en) | 2017-05-04 |
| US20130210761A1 (en) | 2013-08-15 |
| CA2795520A1 (en) | 2011-10-13 |
| AU2011237682B2 (en) | 2016-04-21 |
| CA2795520C (en) | 2018-03-06 |
| EP2555760A1 (en) | 2013-02-13 |
| JP2016033164A (ja) | 2016-03-10 |
| AU2011237682A1 (en) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2773017T3 (es) | Derivados de quitosano para el tratamiento de mucositis o ulceración | |
| ES2665254T3 (es) | Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas | |
| US10471151B2 (en) | Composition for use in treating and preventing inflammation related disorder | |
| US20220168341A1 (en) | Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces | |
| US9173901B2 (en) | Compositions and methods of using lamellar bodies for modifying linear biological macromolecules | |
| ES2402907T3 (es) | Roscovitina para el tratamiento de ciertas enfermedades quísticas | |
| EP3570815B1 (en) | Composition for ophthalmic use | |
| ES3041445T3 (en) | Composition comprising hyaluronic acid and xylitol for use in the treatment of disrupted nasal mucosa and nasal epithelial barrier | |
| Cabral et al. | Toxic epidermal necrolysis-Lyell's syndrome | |
| EP3967300B1 (en) | Composition for the prevention and treatment of infections and/or inflammations | |
| US20160193343A1 (en) | Composition for use in treating and preventing inflammation related disorder | |
| EP1667693A1 (en) | Compositions and methods of using lamellar bodies for therapeutic purposes | |
| NZ611857B2 (en) | Composition for use in treating and preventing inflammation related disorder |